By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


EUSA Pharma 

New York City  New York    U.S.A.
Phone: Fax:



Start Up

Company News
EUSA Pharma Receive Positive Opinion From The CHMP For Tivozanib For The First-Line Treatment Of Advanced Renal Cell Carcinoma In The European Union 6/23/2017 6:32:09 AM
European Commission (EC) Approves EUSA Pharma’s Dinutuximab Beta For The Treatment Of Patients With High-Risk Neuroblastoma 5/10/2017 8:51:17 AM
EUSA Pharma And APEIRON Receive Positive CHMP Opinion For Dinutuximab Beta For The Treatment Of High-Risk Neuroblastoma In Europe 3/27/2017 7:04:19 AM
EUSA Pharma Acquires Global Rights To Neuroblastoma Treatment Isqette (Dinutuximab Beta) From Aperion Biologics 10/4/2016 10:46:26 AM
EUSA Pharma Announces Acquisition Of Global Rights To Next Generation Oncology Supportive Care Product Arcoral Tab From Arcoral Pharma 4/12/2016 6:04:15 AM
EUSA Pharma And AVEO Oncology (AVEO) Announce Submission Of Marketing Authorization Application For Tivozanib In Advanced Renal Cell Carcinoma 3/1/2016 10:44:50 AM
AVEO Oncology (AVEO), EUSA Pharma Form $396.5 Million Exclusive Licensing Agreement for Tivozanib in Europe 12/21/2015 7:34:28 AM
EUSA Pharma Appoints William W Crouse To Its Board Of Directors 9/9/2015 7:36:49 AM
EUSA Pharma Appoints Lee Morley As Chief Executive And Industry Veteran Göran Ando To Board Of Directors 4/21/2015 9:28:27 AM
EUSA Pharma Successfully Launches As An Independent Profitable Pharmaceutical Business With Global Reach And A Portfolio Of Specialty Products Acquired From Jazz Pharmaceuticals (JAZZ) 3/23/2015 8:25:54 AM